260 related articles for article (PubMed ID: 30530828)
1. DOTA-MGS5, a New Cholecystokinin-2 Receptor-Targeting Peptide Analog with an Optimized Targeting Profile for Theranostic Use.
Klingler M; Summer D; Rangger C; Haubner R; Foster J; Sosabowski J; Decristoforo C; Virgolini I; von Guggenberg E
J Nucl Med; 2019 Jul; 60(7):1010-1016. PubMed ID: 30530828
[TBL] [Abstract][Full Text] [Related]
2. Effects of Side Chain and Peptide Bond Modifications on the Targeting Properties of Stabilized Minigastrin Analogs.
Zavvar TS; Hörmann AA; Klingler M; Summer D; Rangger C; Desrues L; Castel H; Gandolfo P; von Guggenberg E
Pharmaceuticals (Basel); 2023 Feb; 16(2):. PubMed ID: 37052226
[TBL] [Abstract][Full Text] [Related]
3. Site-specific stabilization of minigastrin analogs against enzymatic degradation for enhanced cholecystokinin-2 receptor targeting.
Klingler M; Decristoforo C; Rangger C; Summer D; Foster J; Sosabowski JK; von Guggenberg E
Theranostics; 2018; 8(11):2896-2908. PubMed ID: 29896292
[TBL] [Abstract][Full Text] [Related]
4. Targeting of the Cholecystokinin-2 Receptor with the Minigastrin Analog
Sauter AW; Mansi R; Hassiepen U; Muller L; Panigada T; Wiehr S; Wild AM; Geistlich S; Béhé M; Rottenburger C; Wild D; Fani M
J Nucl Med; 2019 Mar; 60(3):393-399. PubMed ID: 30002107
[TBL] [Abstract][Full Text] [Related]
5. Preclinical Evaluation of Minigastrin Analogs and Proof-of-Concept [
Günther T; Holzleitner N; Viering O; Beck R; Wienand G; Dierks A; Pfob CH; Bundschuh RA; Kircher M; Lapa C; Wester HJ
J Nucl Med; 2024 Jan; 65(1):33-39. PubMed ID: 37945383
[TBL] [Abstract][Full Text] [Related]
6. Initial In Vitro and In Vivo Evaluation of a Novel CCK2R Targeting Peptide Analog Labeled with Lutetium-177.
Hörmann AA; Klingler M; Rezaeianpour M; Hörmann N; Gust R; Shahhosseini S; Guggenberg EV
Molecules; 2020 Oct; 25(19):. PubMed ID: 33049999
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo characterization of three 68Ga- and 111In-labeled peptides for cholecystokinin receptor imaging.
Roosenburg S; Laverman P; Joosten L; Eek A; Rutjes FP; van Delft FL; Boerman OC
Mol Imaging; 2012; 11(5):401-7. PubMed ID: 22954184
[TBL] [Abstract][Full Text] [Related]
8. Cholecystokinin-2 Receptor Targeting with Novel C-terminally Stabilized HYNIC-Minigastrin Analogs Radiolabeled with Technetium-99m.
Klingler M; Rangger C; Summer D; Kaeopookum P; Decristoforo C; von Guggenberg E
Pharmaceuticals (Basel); 2019 Jan; 12(1):. PubMed ID: 30650563
[TBL] [Abstract][Full Text] [Related]
9. Automated Synthesis of
Hörmann AA; Plhak E; Klingler M; Rangger C; Pfister J; Schwach G; Kvaternik H; von Guggenberg E
Molecules; 2022 Mar; 27(6):. PubMed ID: 35335396
[TBL] [Abstract][Full Text] [Related]
10. Preliminary Clinical Experience with Cholecystokinin-2 Receptor PET/CT Using the
von Guggenberg E; Uprimny C; Klinger M; Warwitz B; Sviridenko A; Bayerschmidt S; di Santo G; Virgolini IJ
J Nucl Med; 2023 Jun; 64(6):859-862. PubMed ID: 36657979
[TBL] [Abstract][Full Text] [Related]
11. "To serve and protect": enzyme inhibitors as radiopeptide escorts promote tumor targeting.
Nock BA; Maina T; Krenning EP; de Jong M
J Nucl Med; 2014 Jan; 55(1):121-7. PubMed ID: 24287321
[TBL] [Abstract][Full Text] [Related]
12. Effect of
Hörmann AA; Klingler M; Rangger C; Mair C; Joosten L; Franssen GM; Laverman P; von Guggenberg E
Pharmaceutics; 2023 Feb; 15(3):. PubMed ID: 36986657
[TBL] [Abstract][Full Text] [Related]
13. Cholecystokinin 2 Receptor Agonist
Rottenburger C; Nicolas GP; McDougall L; Kaul F; Cachovan M; Vija AH; Schibli R; Geistlich S; Schumann A; Rau T; Glatz K; Behe M; Christ ER; Wild D
J Nucl Med; 2020 Apr; 61(4):520-526. PubMed ID: 31519804
[TBL] [Abstract][Full Text] [Related]
14. Investigation of the structure-activity relationship at the N-terminal part of minigastrin analogs.
Holzleitner N; Günther T; Daoud-Gadieh A; Lapa C; Wester HJ
EJNMMI Res; 2023 Jul; 13(1):65. PubMed ID: 37421545
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological inhibition of mTORC1 increases CCKBR-specific tumor uptake of radiolabeled minigastrin analogue [
Grzmil M; Qin Y; Schleuniger C; Frank S; Imobersteg S; Blanc A; Spillmann M; Berger P; Schibli R; Behe M
Theranostics; 2020; 10(24):10861-10873. PubMed ID: 33042258
[No Abstract] [Full Text] [Related]
16.
Rangger C; Klingler M; Balogh L; Pöstényi Z; Polyak A; Pawlak D; Mikołajczak R; von Guggenberg E
Mol Pharm; 2017 Sep; 14(9):3045-3058. PubMed ID: 28728415
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]